Implant Sciences Corporation (OTCQB:IMSC), a leading manufacturer of explosives trace detection (ETD) and drugs trace detection solutions for homeland security applications, today announced that it has sold 13 of its QS-B220 desktop explosives trace detectors to a second airport in Belgium.
In a span of approximately two months, Implant Sciences has announced a number of major ETD sales to international airports in Europe, totaling up to 500 units across five countries.
"Implant Sciences has again been selected as the optimal vendor for ETDs in a competitive bidding process in the EU. Our strategy and execution has been nothing short of relentless, and our next-generation technology continues to be adopted by major customers" stated Dr. Darryl Jones, Vice President of Global Sales and Marketing for Implant Sciences. "The number of customer reference sites we have increases by the week, and going forward, we believe that our reputation for excellence will continue to propel us, not only in the aviation space, but in other verticals as well."
"We believe that, with every tender we are awarded, Implant Sciences is changing not only our company's trajectory, but also the shape of the ETD marketplace," added Dr. Bill McGann, Implant Sciences' CEO. "Our success story is founded on the simple strategy of delivering the best technology to security operators, which is resulting in a growing wave of market victories. We believe Implant Sciences' superior product offering and service are impacting the ETD landscape, and our satisfied customers are recognizing us as the emerging market leaders."
Source: Implant Sciences Corporation
Date: Jun 22, 2015